Intuitive (NASDAQ:ISRG), a global technology leader in minimally
invasive care and the pioneer of robotic-assisted surgery,
announced today it intends to establish a direct presence in Italy,
Spain, Portugal, Malta, and San Marino, and associated territories
via the acquisition of the da Vinci and Ion distribution businesses
in these countries.
Intuitive has entered into this agreement, subject to regulatory
approvals, with the current Intuitive technology distributors ab
medica, Abex, Excelencia Robotica, and their affiliates to purchase
their Intuitive product-related business. The transaction will not
close until 2026, after approvals have been received and closing
conditions met.
“Intuitive is excited to continue to invest in the significant
opportunity to bring safe, minimally invasive care to more patients
across Europe,” said Intuitive CEO Gary Guthart. “Having a direct
presence in Italy, Spain, Portugal, Malta, and San Marino, and
associated territories allows us to deepen our understanding of
unique customer needs in these countries.”
Upon deal closure in 2026, the da Vinci and Ion business of ab
medica, Abex, and Excelencia Robotica will be wholly owned by
Intuitive, and business operations will be integrated into
Intuitive’s European commercial and marketing organization, led by
Senior Vice President and General Manager Dirk Barten.
“Intuitive is grateful for the years of strong business and
dedication these companies have provided—their leadership has
helped establish robotic technology with physicians and their
patients in Europe,” said Barten.
“We look forward to integrating these teams upon deal closure,”
said Barten. “Developing direct relationships with customers in
these countries is critical for building greater patient access to
minimally invasive care.”
“We are proud to have introduced robotic-assisted surgery more
than two decades ago in Italy and Southern Europe, as one of the
first da Vinci distributors in the world. In 2026 we will continue
on our path of innovation in service of patients, care, and
healthcare professionals,” said ab medica CEO Francesca
Cerruti.
“Over the past forty years, we have become distributors of major
technologies across numerous clinical specialties and become
producers of solutions and services for smart and digital health.
We will continue this journey, and we thank those who have believed
with us in da Vinci surgery, and Intuitive for the trust they have
placed in us,” said Cerruti.
About Intuitive Surgical, Inc.Intuitive
(NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global
leader in minimally invasive care and the pioneer of robotic
surgery. Our technologies include the da Vinci surgical system and
the Ion endoluminal system. By uniting advanced systems,
progressive learning, and value-enhancing services, we help
physicians and their teams optimize care delivery to support the
best outcomes possible. At Intuitive, we envision a future of care
that is less invasive and profoundly better, where disease is
identified early and treated quickly, so that patients can get back
to what matters most.
About da Vinci Surgical SystemsThere are
several models of the da Vinci Surgical System. The da Vinci
surgical systems are designed to help surgeons perform minimally
invasive surgery and offer surgeons high-definition 3D vision, a
magnified view, and robotic and computer assistance. They use
specialized instrumentation, including a miniaturized surgical
camera and wristed instruments (i.e., scissors, scalpels, and
forceps) that are designed to help with precise dissection and
reconstruction deep inside the body.
About the Ion Endoluminal SystemThe Ion
Endoluminal System (Model IF1000) assists the user in navigating a
catheter and endoscopic tools in the pulmonary tract using
endoscopic visualization of the tracheobronchial tree for
diagnostic and therapeutic procedures. The Ion Endoluminal System
enables fiducial marker placement. It does not make a diagnosis and
is not for pediatric use.
Information provided by the Ion Endoluminal System or its
components should be considered guidance only and not replace
clinical decisions made by a trained physician.
For more information, please visit the company’s website
at www.intuitive.com.
Important Safety InformationFor important
safety information, indications for use, risks, full cautions and
warnings, please refer to www.intuitive.com/safety.
Forward-Looking StatementsThis press release
contains forward-looking statements which relate to expectations
concerning matters that are not historical facts. Statements using
words such as “estimates,” “projects,” “believes,” “anticipates,”
“plans,” “expects,” “intends,” “may,” “will,” “could,” “should,”
“would,” “targeted,” and similar words and expressions are intended
to identify forward-looking statements. These forward-looking
statements are necessarily estimates reflecting the judgment of the
Company’s management and involve a number of risks and
uncertainties that could cause actual results or impacts on the
Company’s operations, financial performance, and market position to
differ materially from those suggested by the forward-looking
statements. These forward-looking statements include, but are not
limited to, statements related to establishing a direct presence in
Italy, Spain, Portugal, Malta, and San Marino, and associated
territories, the expected closing timeframe of the transaction,
obtaining regulatory approvals, bringing care to more patients
across Europe, integration of business operations and teams,
developing direct relationships with customers, continuing
innovation in service of patients, care, and health care
professionals. These forward-looking statements should be
considered in light of various important factors and involve known
and unknown risks, uncertainties, and other factors, which may
cause the actual results, performance, or achievements of the
Company, or industry results, to be materially different from any
future results, performance, or achievements expressed or implied
by such forward-looking statements. Important factors that could
cause actual results to differ materially from those anticipated in
the forward-looking statements include, among others, economic
conditions in the markets in which we operate, changes in
governmental regulations, regulatory enforcement priorities, and
other factors discussed in the Company’s Annual Reports and other
filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release and which are based on current expectations and are
subject to risks, uncertainties, and assumptions that are difficult
to predict, including those risk factors identified under the
heading “Risk Factors” in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, as updated by the Company’s
other filings with the Securities and Exchange Commission. The
Company’s actual results may differ materially and adversely from
those expressed in any forward-looking statement, and the Company
undertakes no obligation to publicly update or release any
revisions to these forward-looking statements, except as required
by law.
PRESS CONTACTU.S.: Peper Long,
Intuitive202-446-7748 – mobilepeper.long@intusurg.com
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Intuitive Surgical (NASDAQ:ISRG)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025